Novo Nordisk has announced plans to acquire Akero Therapeutics for *$4.7 billion upfront, marking a major expansion into the *metabolic dysfunction-associated steatohepatitis (MASH) market. The deal underscores the Danish company’s ambition to dominate treatments in obesity-related liver disease, following FDA approval for adding MASH to the label of its GLP-1 drug semaglutide (Wegovy).
Key Points
- Acquisition Details
- Novo Nordisk will pay $54 per share in cash for Akero Therapeutics.
- An additional $6 per share (approx. $500 million) will be paid if Akero’s lead drug efruxifermin (EFX) wins U.S. FDA approval.
- Total potential deal value: $5.2 billion.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
